Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Astellas Pharma
Astellas Pharma
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Samsung Biologics signs $1.24bn biopharma manufacturing deal with Asian pharmaceutical giant
The CDMO will work with the client until the end of 2037, and will use its South Korean biomanufacturing site to serve them
Bespak and H&T Presspart announce availability of GMP pilot line for climate-friendly pMDIs
Filling line is on track to supply clinical trial batches utilising climate-friendly propellants HFA-152a and HFO-1234ze
Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma
The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Axol Bioscience boosts its iPSC bioassay offering with Phenocell acquisition
The acquisition will extend Axol's range of iPSC-derived cell lines, including skin and retinal cells — while also expanding its drug discovery services
How AI and GenAI will revolutionise the healthcare industry
Artificial intelligence — and particularly its newest iteration, generative artificial intelligence (GenAI) — could bring significant changes to the way we live, work and...
Upcoming event
Lab Innovations
30-31 October 2024 | Exhibition | Birmingham, UK
See all
Related Content
Regulatory
Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma
The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Regulatory
Padcev plus Keytruda approved for advanced urothelial cancer by the EC
The therapeutic combination will now be named as the first-line, standard of care treatment for metastatic or advanced bladder cancer
Research & Development
Astellas Pharma doses first patient in Phase III trial for Fezolinetant
Fezolinetant aims to mitigate the impact of hot flushes, which are the most common side effect associated with endocrine therapy for breast cancer
Manufacturing
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Regulatory
Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics
Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Manufacturing
Astella invests $3.5m in antibody drug facility
Drug producer Astella is set to submit a planning application to build a new facility in Tralee (County Kerry), Ireland, to expand its capacity to develop antibody drugs
Ingredients
Therapeutic: zolbetuximab for gastric cancer
Stomach cancer is the fifth most commonly diagnosed form of cancer, with risk factors including age, smoking, H. pylori infection and gastro-oesophageal reflux disease
Subscribe now